CRISPR Technology Market – Top 3 Players and there Market Growth
The CRISPR technology market include the rising funding from government and private organizations and the high adoption of CRISPR technology.
The global CRISPR Technology market size is projected to reach USD 562 million in 2018 to USD 1,715 million by 2023, at a CAGR of 25%.
Cellecta, Inc. (US), Thermo Fisher (US), GeneCopoeia, Inc. (US), Applied StemCell (US), Synthego Corporation (US), OriGene Technologies (US), Horizon Discovery (UK), Merck (Germany), and GenScript (US) are some key players in this market. These companies are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies such as product launches, acquisitions, and expansions.
For More Details, Download a PDF Brochure:-
“Thermo Fisher Scientific has established its presence in diversified life sciences markets; this has helped it to minimize risks and dependency on any particular business segment”
The company has a strong product portfolio and brand image, which enables it to strengthen its position in the market. It has strong R&D capabilities, which provide it a strategic advantage over its competitors. The company focuses on obtaining market-driven solutions to meet the increasing demand for CRISPR-edited genes. It is involved in various growth initiatives such as product launches and agreements. For instance, in 2015, Thermo Fisher Scientific signed a license agreement, to be renewed yearly, with ToolGen (South Korea) for ToolGen’s intellectual property portfolio of CRISPR-Cas9 technology.
“Merck is also an established player in the life sciences industry”
The company leads in terms of operational and financial strength and has focused on growth in the CRISPR technology market through organic growth strategies. Merck was also the first company to manufacture arrayed CRISPR libraries that covered the entire human genome. This was done in collaboration with the Wellcome Trust Sanger Institute. These arrayed CRISPR libraries helped researchers in drug discovery, disease research, and gene therapy. Arrayed CRISPR libraries have been an important technological advancement in genome editing and helped Merck in attaining the leadership position. It has acquired patents for its CRISPR technology in Australia, China, Canada, Europe, and Korea for its in-house alternate CRISPR technology. In 2018, Merck partnered with Tongji University (China) and offered its genome-editing technology to Tongji University under the CRISPR Core Partnership Program, which has brought together around 82 organizations using CRISPR technology.
We can help with your specific research requirement for this market. Please share your specific interest to help us serve you better, Request Sample Pages:-